|
|
Volumn 58, Issue 2, 2006, Pages 125-127
|
|
Drug delivery in degenerative joint disease: Where we are and where to go?
a
a
NONE
|
|
Author keywords
Osteoarthritis; Pain management; Toxicity
|
|
Indexed keywords
BIOLOGICAL ORGANS;
DISEASES;
JOINTS (ANATOMY);
PATIENT TREATMENT;
TOXICITY;
JOINT TISSUES;
OSTEOARTHRITIS;
PAIN MANAGEMENT;
DRUG PRODUCTS;
AMG 108;
ANALGESIC AGENT;
ANTIRHEUMATIC AGENT;
BISPHOSPHONIC ACID DERIVATIVE;
CAPSAICIN;
CHONDROITIN;
CORTICOSTEROID;
CYTOKINE RECEPTOR ANTAGONIST;
DIACETYLRHEIN;
DOXYCYCLINE;
ENZYME INHIBITOR;
GLUCOSAMINE;
HYALURONIC ACID;
INDUCIBLE NITRIC OXIDE SYNTHASE;
INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR;
INTERLEUKIN 1 ANTIBODY;
INTERLEUKIN 1BETA INHIBITOR;
METALLOPROTEINASE INHIBITOR;
NANOPARTICLE;
NONSTEROID ANTIINFLAMMATORY AGENT;
NUTRACEUTICAL;
PARACETAMOL;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RECOMBINANT PROTEIN;
RECOMBINANT RNA;
UNCLASSIFIED DRUG;
ARTICLE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
DISEASE COURSE;
DRUG BIOAVAILABILITY;
DRUG DELIVERY SYSTEM;
DRUG EXPOSURE;
DRUG FORMULATION;
GENE THERAPY;
HUMAN;
JOINT FUNCTION;
OSTEOARTHRITIS;
PAIN;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SUSTAINED RELEASE PREPARATION;
|
|
EID: 33646177837
PISSN: 0169409X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.addr.2006.01.005 Document Type: Note |
|
Times cited : (23)
|
|
References (0)
|
